Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania Show more
Location: 125 Strafford Avenue, Wayne, PA, 19087, United States | Website: https://palvellatx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
306.2M
52 Wk Range
$7.21 - $29.27
Previous Close
$27.70
Open
$27.80
Volume
30,635
Day Range
$26.98 - $28.00
Enterprise Value
186.7M
Cash
75.63M
Avg Qtr Burn
-4.127M
Insider Ownership
22.87%
Institutional Own.
47.68%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
QTORIN Rapamycin Details Microcystic Lymphatic Malformations | Phase 3 Data readout |